Is ipamorelin legal in Australia?

The short answer

In Australia, ipamorelin is treated as a prescription-only substance under the Poisons Standard. It is captured within the growth hormone secretagogue (GHS) class, which is listed in Schedule 4, and it also sits within Appendix D (Part 5), a part of the Standard that applies additional restrictions to certain substances. In plain terms, ipamorelin is not a freely available consumer product. It is also not an approved medicine on the Australian Register of Therapeutic Goods (ARTG), and growth hormone secretagogues are prohibited in sport at all times under anti-doping rules.

NovaPeptides supplies ipamorelin strictly as a research chemical for laboratory research use only. It is not sold or supplied for human use, and nothing on this page should be read as encouragement to use it in people.

How the TGA and Poisons Standard classify it

Medicines and poisons in Australia are classified through the Poisons Standard, also known as the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). This document is maintained by the Therapeutic Goods Administration (TGA) and sorts substances into schedules that determine how they may be supplied, accessed and advertised.

Growth hormone secretagogues, the broad class that includes ipamorelin, are handled as a group within the Poisons Standard. Rather than listing every peptide individually in isolation, the Standard uses class entries for growth hormone releasing peptides (GHRPs), growth hormone releasing hormones (GHRHs) and growth hormone secretagogues (GHSs). TGA scheduling records associated with this class name ipamorelin alongside related substances such as CJC-1295, hexarelin, GHRP-6 and pralmorelin.

Two parts of the Standard are relevant here. Schedule 4 covers prescription-only medicines, meaning lawful human access generally requires a prescription from an authorised health practitioner and supply through appropriate channels. Appendix D lists substances subject to additional controls on their availability. Ipamorelin falls within the growth hormone secretagogue class that is treated under both of these headings.

What the classification means in practice

• It is not an over-the-counter or general retail consumer product.
• Lawful human supply in Australia is tied to the prescription-only framework.
• Additional restrictions under Appendix D apply to this class of substance.
• The exact wording and schedule entries can change, so the live Poisons Standard is the authoritative source.

It is not an approved medicine on the ARTG

Being scheduled is not the same as being approved. The Australian Register of Therapeutic Goods (ARTG) is the list of medicines and other therapeutic goods that the TGA has evaluated and approved for supply in Australia for a defined therapeutic purpose. Ipamorelin is not entered on the ARTG as an approved medicine for human therapeutic use.

This distinction matters. A substance can appear in the Poisons Standard, which governs how things are scheduled and controlled, without ever having been assessed and approved as a finished therapeutic product. In the case of ipamorelin, there is no TGA approval establishing it as a safe and effective medicine for any human condition. For that reason, no claims about treating, preventing, curing or improving any condition can be made about it.

Research use only versus an approved medicine

There is a clear line between a research chemical and an approved medicine. An approved medicine has been through regulatory evaluation, carries approved labelling and directions, and is intended to be supplied for use in people. A research chemical is a substance supplied for laboratory and scientific investigation only. It is not formulated, labelled or intended for human consumption.

Ipamorelin, as supplied by NovaPeptides, sits firmly in the second category. It is a research material intended for in-vitro and laboratory research conducted by qualified researchers and institutions. It is not a therapeutic good, it is not a dietary supplement, and it is not a product for personal human use. Keeping this distinction clear is central to handling the substance lawfully and responsibly.

What ipamorelin is, in neutral terms

Ipamorelin is a synthetic pentapeptide, meaning a small peptide built from five amino acid residues. In scientific literature it is described as a selective growth hormone secretagogue and a ghrelin-receptor agonist. The ghrelin receptor is also referred to as the growth hormone secretagogue receptor (GHS-R).

In mechanistic terms described in research settings, ipamorelin binds to and activates the ghrelin receptor. Agonists of this receptor are studied for their interaction with pathways associated with the release of growth hormone from the pituitary gland in various model systems. Ipamorelin is often characterised in the literature as relatively selective compared with some other secretagogues. These are descriptions of how the molecule is studied, not statements that it produces any particular effect or benefit in humans.

Because it belongs to the growth hormone secretagogue family, ipamorelin is grouped with peptides such as the GHRPs and with related compounds in both regulatory and anti-doping frameworks, which is why it is captured by the class-based approach described above.

WADA and sport status

Ipamorelin is prohibited in sport. Under the World Anti-Doping Agency (WADA) Prohibited List, growth hormone secretagogues sit in category S2, which covers peptide hormones, growth factors, related substances and mimetics. Sport Integrity Australia lists ipamorelin within this category, specifically as a class S2.2 substance, and classifies it as prohibited at all times, meaning both in-competition and out-of-competition.

For any athlete who competes under anti-doping rules, this means the presence, use or possession of ipamorelin can constitute an anti-doping rule violation. The S2 category is also written to capture substances with a similar chemical structure or similar biological effect, so related secretagogues are treated the same way. Athletes should always check the current Prohibited List and consult the Global DRO or their anti-doping authority before anything.

A note on importation and access

Because ipamorelin is treated within a prescription-only class under the Poisons Standard, importing or supplying it for human use is governed by Commonwealth and state or territory rules that apply to Schedule 4 substances. Bringing scheduled substances into Australia can engage both TGA import requirements and border controls, and the rules differ depending on the purpose, quantity and documentation involved.

This guide does not set out a method for obtaining ipamorelin for personal use, and NovaPeptides does not assist anyone to do so. If you have questions about the legality of importing or possessing a scheduled substance in your specific circumstances, seek advice from the TGA, your state or territory health department, or a qualified legal professional.

How NovaPeptides supplies ipamorelin

NovaPeptides lists ipamorelin as a research chemical for laboratory research use only. Every order is supplied on that basis. The material is intended for qualified researchers and research organisations carrying out in-vitro or laboratory work, and it is not offered, sold or promoted for human use, veterinary use, or as a supplement.

We do not provide dosing instructions, human-use protocols, or therapeutic guidance, and we make no claims that ipamorelin treats, prevents or improves any condition. Customers are responsible for understanding and complying with the laws that apply to research materials in their own jurisdiction, including the current Poisons Standard and any institutional requirements.

If you are a researcher evaluating ipamorelin or related peptides for a legitimate research programme, our catalogue entries set out the available presentations. For anything concerning legal status or compliance in your situation, rely on the official sources rather than this general overview.

Frequently asked questions